Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919479 | 0.84 | CHRNB2 (0.39) | CHRNB2CHRNA4LMNAHTTMEN1 | |
| SCHEMBL388491 | 0.83 | KDM4E (0.47) | — | |
| SCHEMBL23523234 | 0.82 | CHRNB2 (0.46) | CHRNB2CHRNA4LMNAHTTMEN1 | |
| SCHEMBL23933677 | 0.82 | CHRNB2 (0.46) | CHRNB2CHRNA4LMNAHTTMEN1 | |
| SCHEMBL3842144 | 0.81 | GRIN2B (0.43) | GRIN2B | |
| SCHEMBL410479 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL22609209 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4LMNAHTTACHE | |
| SCHEMBL2705546 | 0.80 | FFAR4 (0.39) | ACHEMEN1KMT2AGRIN2BFFAR4 | |
| SCHEMBL5272344 | 0.80 | GPR119 (0.43) | LMNAHTTLIPEMEN1KMT2A | |
| SCHEMBL4259566 | 0.79 | CHRNA3 (0.53) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008025799-A1 | PYRIDAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| US-20080058339-A1 | New compounds | BIOVITRUM (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058339-A1 | New compounds | GPR119, GPR180, GPR139 | CHRNB2 384/4885CHRNA4 423/4885LMNA 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.